A Randomized Trial Comparing Adjuvant Pembrolizumab vs Standard of Care Observation in Completely Resected Merkel Cell Carcinoma of Skin (EA6174)
A Randomized Trial Comparing Adjuvant Pembrolizumab vs Standard of Care Observation in Completely Resected Merkel Cell Carcinoma of Skin (EA6174)
Trial Category:
Other Solid Tumor
Phase
III
Contact(s)
Location(s)
Methodist Estabrook Cancer Center, Omaha, NE
Current standard of care for patients who have experienced a completely resected Merkel Cell Skin Cancer is to observe the patient at frequent intervals. This is called "Observation". "Standard of Care" is the considered the common guideline used by physicians to manage a certain type of disease. This study is looking at comparing the drug Pembrolizumab to Observation, to assess whether adding the drug after surgery improves the patients overall survival from this cancer.
